How Tirzepatide Works: Dual GIP/GLP-1 Action Explained

Last Updated: March 2026

In the SURMOUNT-1 trial, tirzepatide produced 20.9% weight loss at 72 weeks compared to 3.1% for placebo—nearly double the 14.9% achieved by semaglutide in STEP 1 (NEJM, 2022). The difference lies in tirzepatide’s dual mechanism: it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously.

This combination represents a fundamental shift in obesity pharmacotherapy. While GLP-1 agonists like semaglutide and liraglutide have dominated the weight loss market since 2021, tirzepatide’s dual-receptor approach consistently produces superior outcomes across multiple trials.

The Single-Hormone Limitation

GLP-1 receptor agonists work through a well-established pathway. They mimic the incretin hormone GLP-1, which the gut releases after eating. This triggers insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through central nervous system pathways.

Semaglutide demonstrated this mechanism’s power in the STEP trial program. Participants achieved 14.9% weight loss over 68 weeks—a breakthrough result that led to FDA approval in 2021. But researchers at Eli Lilly had already begun exploring whether adding a second hormone target could push results further.

The GIP receptor offered a compelling target. Like GLP-1, GIP is an incretin hormone secreted by the gut in response to nutrients. Both regulate glucose metabolism and insulin secretion. But GIP’s role in weight regulation remained controversial through the 2010s.

Why GIP Activation Matters

Early obesity research suggested GIP might promote weight gain. Some studies showed that blocking GIP receptors reduced body weight in animal models. This led researchers to initially pursue GIP receptor antagonists—drugs that block the receptor—for obesity treatment.

Those assumptions proved incorrect. In a 2021 Nature paper, researchers at Eli Lilly demonstrated that GIP receptor activation actually enhances weight loss when combined with GLP-1 agonism. The study in mice showed that tirzepatide produced greater weight reduction than selective GLP-1 agonism alone, with the effect dependent on intact GIP receptor signaling.

The mechanism appears multifaceted. GIP receptor activation increases adiponectin levels, an adipokine that regulates glucose and lipid metabolism. Higher adiponectin correlates with improved insulin sensitivity and reduced inflammation. In the SURPASS-2 trial, tirzepatide increased adiponectin by 26% to 42% depending on dose, while semaglutide showed no significant effect (Diabetes, 2021).

GIP may also enhance fat oxidation. Studies using indirect calorimetry show that tirzepatide shifts fuel utilization toward fat metabolism more effectively than pure GLP-1 agonists. This could explain why dual agonism produces greater fat mass reduction relative to lean mass preservation.

The receptor distribution matters too. While both GIP and GLP-1 receptors appear in the pancreas and brain, GIP receptors show higher expression in adipose tissue. This allows tirzepatide to potentially target fat stores more directly than GLP-1 monotherapy.

Clinical Evidence: Head-to-Head Comparisons

The SURMOUNT trials established tirzepatide’s superiority across multiple endpoints. SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus weight-related complications. At 72 weeks, the 15 mg tirzepatide dose produced 20.9% weight loss versus 3.1% for placebo.

Breaking down the responder rates reveals the consistency: 91% of participants on 15 mg tirzepatide lost at least 5% body weight, 69% lost at least 15%, and 50% lost at least 20%. Those numbers surpass every other approved obesity medication.

The SURMOUNT-2 trial focused specifically on participants with type 2 diabetes—a population that typically shows more modest weight loss. Even here, tirzepatide delivered 14.7% weight reduction at the highest dose versus 3.2% for placebo over 72 weeks (NEJM, 2023).

Direct comparisons to semaglutide come from the SURPASS-2 trial in diabetes patients. Participants taking 15 mg tirzepatide lost 12.4 kg versus 6.2 kg with 1 mg semaglutide at 40 weeks. The dual agonist produced twice the weight loss of the GLP-1-only drug in the same patient population.

Molecular Structure and Receptor Binding

Tirzepatide’s molecular design explains how it activates both receptors effectively. The drug consists of a 39-amino acid peptide based on the native GIP sequence, with modifications that enable GLP-1 receptor activation. This differs from sequential dosing of two separate drugs.

According to the FDA prescribing information, tirzepatide shows higher potency at the GIP receptor than the GLP-1 receptor. In cell-based assays, the drug’s EC50 (half-maximal effective concentration) is 0.05 nM at GIP receptors versus 0.96 nM at GLP-1 receptors—roughly 20-fold more potent at GIP.

This biased agonism appears intentional. The greater GIP activation may compensate for lower GLP-1 potency compared to pure GLP-1 agonists like semaglutide. The net effect produces superior metabolic outcomes despite different individual receptor potencies.

The drug also includes a C20 fatty diacid chain that enables albumin binding. This extends the half-life to approximately 5 days, allowing once-weekly subcutaneous dosing identical to semaglutide’s schedule.

Metabolic Effects Beyond Weight Loss

Tirzepatide’s dual action produces metabolic improvements that extend beyond the scale. In SURMOUNT-1, 94.4% of participants with prediabetes at baseline showed normal glucose levels by 72 weeks on the 15 mg dose. This diabetes prevention effect exceeds historical data for lifestyle intervention.

Lipid profiles improved substantially. Triglycerides decreased by 23% to 30% depending on dose, while HDL cholesterol increased by 7% to 9%. These changes occurred independent of weight loss magnitude, suggesting direct metabolic effects from dual receptor activation.

Blood pressure reductions averaged 7.4 to 9.6 mmHg systolic across tirzepatide doses in SURMOUNT-1. Cardiovascular risk factor improvements prompted the ongoing SURMOUNT-MMO trial, which will assess cardiovascular outcomes in 15,000 participants through 2026.

The liver benefits particularly from tirzepatide treatment. In participants with non-alcoholic fatty liver disease, hepatic fat content decreased by 8.09 percentage points with 15 mg tirzepatide versus 1.19 points with placebo at 72 weeks. Liver enzymes normalized in parallel, indicating resolution of steatohepatitis in many cases.

Dosing Strategy and Titration

Tirzepatide follows an escalation schedule designed to minimize gastrointestinal side effects. Treatment begins at 2.5 mg once weekly for four weeks, then increases to 5 mg for at least four weeks. Further increases to 7.5 mg, 10 mg, 12.5 mg, and 15 mg occur at four-week intervals as tolerated.

This gradual titration differs from semaglutide’s approach. Where semaglutide increases monthly from 0.25 mg to 2.4 mg over 16 weeks, tirzepatide can take up to 24 weeks to reach maximum dose. The extended ramp-up period allows the GI tract to adapt to both GIP and GLP-1 receptor activation.

Clinical trial data show the highest dose produces the best outcomes. The 15 mg dose in SURMOUNT-1 resulted in 20.9% weight loss compared to 15.0% at 10 mg and 16.1% at 5 mg. But not all participants tolerate maximum dosing.

In practice, 9.8% of participants discontinued tirzepatide due to adverse events in SURMOUNT-1, compared to 2.6% on placebo. Nausea, diarrhea, and vomiting accounted for most discontinuations. Finding an individual’s optimal dose balances efficacy against tolerability.

Side Effect Profile and GI Tolerance

The dual receptor activation creates a familiar side effect pattern. Nausea affected 31.7% of participants on 15 mg tirzepatide in SURMOUNT-1, versus 6.5% on placebo. Diarrhea occurred in 23.0% versus 9.5%, and vomiting in 12.2% versus 1.7%.

These rates align with GLP-1 agonist class effects. Slowed gastric emptying from both GIP and GLP-1 activation causes most GI symptoms. The effects typically peak during dose escalation periods and diminish with continued use.

Serious adverse events occurred in 6.8% of tirzepatide participants versus 4.6% on placebo. The difference stems primarily from acute pancreatitis (3 cases on tirzepatide, 0 on placebo) and acute cholecystitis (6 cases versus 1). Both conditions relate to rapid weight loss rather than direct drug toxicity.

Gallstone formation increases with any weight loss medication. Tirzepatide’s rapid weight reduction—participants lost an average of 21 kg over 72 weeks—creates supersaturated bile that crystallizes into stones. This explains the 2.7% incidence of cholelithiasis on tirzepatide versus 0.6% on placebo.

Comparison Table: Tirzepatide vs. Semaglutide

Unanswered Questions

The field lacks long-term safety data beyond three years. Whether dual GIP/GLP-1 agonism carries different cardiovascular or renal risks than GLP-1 monotherapy remains unclear. The SELECT trial demonstrated semaglutide’s cardiovascular benefits in 2023, but comparable tirzepatide data won’t arrive until SURMOUNT-MMO completes.

GIP’s role in cognitive function deserves more research. Both GIP and GLP-1 receptors appear in brain regions controlling appetite and reward. Some preclinical evidence suggests GIP receptor activation improves cognitive performance in animal models. Whether this translates to humans awaits dedicated neurocognitive trials.

The optimal dosing strategy also remains debatable. Some patients respond maximally to 10 mg dosing, while others require 15 mg for full effect. No validated predictors identify which individuals will respond best to which dose before starting treatment.

Long-term weight maintenance after discontinuation poses practical questions. Early data from extension studies show that stopping tirzepatide results in gradual weight regain, similar to patterns seen with other weight loss medications. This suggests obesity pharmacotherapy may require indefinite continuation for sustained benefits.

Triple Agonism and Future Developments

Researchers are already exploring triple agonist molecules that add glucagon receptor activation to the GIP/GLP-1 combination. Retatrutide, currently in Phase 3 trials, targets all three receptors and produced 24.2% weight loss at 48 weeks in early studies.

Whether adding glucagon receptor agonism improves outcomes beyond dual agonism remains uncertain. Glucagon primarily drives glucose production and energy expenditure. The theoretical benefit involves increased metabolic rate and fat oxidation, but clinical data remain limited.

Other pharmaceutical companies are developing their own dual agonists with different receptor selectivity profiles. Some prioritize higher GLP-1 potency relative to GIP, while others explore GLP-1/glucagon combinations without GIP. These variations will eventually reveal which receptor activation ratios produce optimal results.

The Evidence Supports Dual Agonism

Tirzepatide’s clinical performance establishes dual GIP/GLP-1 agonism as superior to GLP-1 monotherapy for weight reduction. The SURMOUNT trials demonstrate consistent 20%+ weight loss across diverse populations when titrated to maximum dose. This exceeds semaglutide’s results by roughly 40% in relative terms.

The mechanism behind this advantage involves more than simple receptor addition. GIP activation appears to enhance metabolic effects through adiponectin upregulation, improved fat oxidation, and potentially direct adipose tissue signaling. These pathways complement GLP-1’s appetite suppression and glucose regulation.

Clinical trial data through 72 weeks show acceptable safety profiles similar to GLP-1 agonists. The GI side effect burden remains the primary tolerability concern, affecting roughly one-third of participants during dose escalation. Serious adverse events occur infrequently and relate primarily to rapid weight loss rather than direct toxicity.

The FDA’s 2023 approval of tirzepatide for chronic weight management reflects this robust evidence base. With head-to-head superiority over semaglutide and the strongest weight loss results for any approved medication, tirzepatide represents the current standard for pharmacologic obesity treatment.

Sources

1. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

2. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management in Adults. November 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-treatment-chronic-weight-management-adults

3. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Nature. 2021;595:721-726. https://www.nature.com/articles/s41586-021-03713-7

4. Frías JP, et al. Efficacy and Safety of Tirzepatide in Patients With Type 2 Diabetes: 52-Week Results From the SURPASS-2 Trial. Diabetes. 2021;70(Supplement 1):28-OR. https://diabetes.diabetesjournals.org/content/70/Supplement_1/28-OR

5. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf